CD8A and plasma cell myeloma: Myeloma patients that received bortezomib treatment followed by lenalidomide maintenance treatment post autologous stem cell transplant (ASCT) showed increase in naïve and memory CD8+ T cells, higher expression of co-stimulatory molecules and reduction in inhibitory checkpoint molecules (33).